Diltiazem relieves capecitabine-induced chest pain

November 16, 2012
Diltiazem relieves capecitabine-induced chest pain
Secondary prophylaxis with diltiazem may offer cancer patients relief from capecitabine-induced chest pain and dyspnea and allow them to tolerate capecitabine treatment, according to a study published in the Dec. 1 issue of The American Journal of Cardiology.

(HealthDay)—Secondary prophylaxis with diltiazem may offer cancer patients relief from capecitabine-induced chest pain and dyspnea and allow them to tolerate capecitabine treatment, according to a study published in the Dec. 1 issue of The American Journal of Cardiology.

Andrew P. Ambrosy, M.D., of the Stanford University School of Medicine in California, and colleagues conducted a small trial involving five patients with primary colorectal adenocarcinoma or anal without significant who started on a two-weeks-on, one-week-off capecitabine dosing regimen. After experiencing chest pain and/or dyspnea at rest or with exertion, patients were started on diltiazem.

The researchers found that, in some cases, at initial presentation, acute electrocardiographic findings were suggestive of ischemia. One patient exhibited troponin elevation which was consistent with acute ST-segment elevation . After discontinuing capecitabine treatment, all five patients had immediate and sustained relief of their chest pain. They were able to tolerate capecitabine treatment after initiating diltiazem and were able to complete multiple subsequent cycles of capecitabine. However, one patient continued to experience milder and less frequent chest pain with heavy exertion, even after diltiazem initiation.

"In patients without ongoing ischemia, in whom capecitabine is clinically indicated (i.e., no alternatives with comparable efficacy and safety), we recommend starting diltiazem, prescribing sublingual nitroglycerin as needed for acute events, and continuing capecitabine therapy with close follow-up," the authors write.

Explore further: FDA OKs Ixempra for advanced breast cancer

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

FDA OKs Ixempra for advanced breast cancer

October 22, 2007

The U.S. Food and Drug Administration has approved Ixempra, a new anti-cancer treatment, for use in patients with metastatic or advanced breast cancer.

Recommended for you

Children should eat less than 25 grams of added sugars daily

August 22, 2016

Children ages 2 to 18 should eat or drink less than six teaspoons of added sugars daily, according to the scientific statement recommending a specific limit on added sugars for children, published in the American Heart Association ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.